	US 11,834,487 B2
	Modulation of SLAMF6 splice variants for cancer therapy
Michal Lotem, Macabbim Reut (IL); Galit Mishan Eisenberg, Modiin (IL); and Emma Hajaj, Netanya (IL)
Assigned to HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., Jerusalem (IL)
Appl. No. 16/968,967
Filed by HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., Jerusalem (IL)
PCT Filed Feb. 11, 2019, PCT No. PCT/IL2019/050163 § 371(c)(1), (2) Date Aug. 11, 2020, PCT Pub. No. WO2019/155474, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/629,129, filed on Feb. 12, 2018.
Prior Publication US 2021/0054043 A1, Feb. 25, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01)

CPC C07K 14/70503 (2013.01) [A61K 39/001111 (2018.08); A61P 35/00 (2018.01); A61K 2039/5152 (2013.01); A61K 2039/575 (2013.01); C07K 2319/02 (2013.01)]

25 Claims

1. A therapeutic cell composition comprising a cell population engineered to express preferentially SLAMF6^var3.